Dongsung Pharm Asset Resilience Ratio
Dongsung Pharm asset resilience ratio. Dongsung Pharm (002210) has an Asset Resilience Ratio of 0.00% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002210 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dongsung Pharm (2008–2022)
Asset resilience ratio of Dongsung Pharm from 2008 to 2022. This chart shows how Dongsung Pharm's Asset Resilience Ratio has changed over time. Read debt load of Dongsung Pharm for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dongsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Dongsung Pharm.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩-1.00K | -0.0% |
| Total Liquid Assets | ₩-1.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Dongsung Pharm maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dongsung Pharm Industry Peers by Asset Resilience Ratio
Compare Dongsung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Dongsung Pharm Asset Resilience Ratio by Year (2008–2022)
Dongsung Pharm asset resilience ratio by year from 2008 to 2022. The table below shows the annual Asset Resilience Ratio data for Dongsung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | ₩-300.00 ≈ $-0.20 |
₩107.70 Billion ≈ $72.99 Million |
-1.91pp |
| 2021-12-31 | 1.91% | ₩2.00 Billion ≈ $1.36 Million |
₩104.58 Billion ≈ $70.87 Million |
-5.30pp |
| 2020-12-31 | 7.22% | ₩9.07 Billion ≈ $6.15 Million |
₩125.72 Billion ≈ $85.20 Million |
-6.89pp |
| 2019-12-31 | 14.10% | ₩18.58 Billion ≈ $12.59 Million |
₩131.73 Billion ≈ $89.27 Million |
-7.31pp |
| 2018-12-31 | 21.41% | ₩30.02 Billion ≈ $20.34 Million |
₩140.20 Billion ≈ $95.01 Million |
+10.23pp |
| 2017-12-31 | 11.18% | ₩13.88 Billion ≈ $9.41 Million |
₩124.18 Billion ≈ $84.16 Million |
-2.59pp |
| 2016-12-31 | 13.76% | ₩17.26 Billion ≈ $11.70 Million |
₩125.39 Billion ≈ $84.97 Million |
+13.14pp |
| 2011-12-31 | 0.62% | ₩774.12 Million ≈ $524.61K |
₩124.58 Billion ≈ $84.42 Million |
-1.17pp |
| 2010-12-31 | 1.79% | ₩2.29 Billion ≈ $1.55 Million |
₩127.81 Billion ≈ $86.61 Million |
-1.96pp |
| 2009-12-31 | 3.75% | ₩4.79 Billion ≈ $3.25 Million |
₩127.91 Billion ≈ $86.68 Million |
+3.42pp |
| 2008-12-31 | 0.33% | ₩405.00 Million ≈ $274.46K |
₩124.57 Billion ≈ $84.42 Million |
-- |
About Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more